Theradex

Quick facts

Phase 2 pipeline

• BBR 3464 · Autoimmune diseases
  BBR 3464 is a small molecule inhibitor of the PI3K delta subunit.
• DHA-paclitaxel · Oncology
  Paclitaxel binds to tubulin, inhibiting microtubule formation and cell division.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Theradex portfolio CI brief
• Theradex pipeline updates RSS